Cognitive interviews were critical for item refinement in the development of the PROMIS measure of sexual function. Efforts are underway to validate the measure in larger cancer populations.”
“Objective: The aim of this study is to examine cognitive skills, adaptive behavior, social and emotional skills in deaf children with cochlear implant (CI) compared to normal hearing children.
Methods: The study included twenty children affected by profound hearing loss implanted with a CI compared to 20 healthy children matched to Go 6983 in vivo chronological age and gender.
Results:
Results of this study indicated that 55% of children with CI showed a score in the normal range of nonverbal intelligence (IQ > 84), 40% in the borderline range
(71 < IQ < 84) and 5% were in mild range (50 < IQ < 70). No significant differences were found after comparison with normal hearing children. Children with CI reported more abnormalities in emotional symptoms (p = .018) and peer problems (p = .037) than children with normal hearing. Age of CI was negatively correlated with IQ (p = .002), positively correlated with emotional symptoms (p = .04) and with peer problems (p = .02).
Conclusions: CI has a positive effect on the lives of deaf children, especially if it is implanted in much earlier ages. (C) 2013 Elsevier Ireland Ltd. All rights reserved.”
“Phytochemical investigation of the leaves of Arctium lappa led to the isolation of two triterpenoids, characterised by NMR, IR and MS as 3 alpha-hydroxylanosta-5,15-diene and 3 alpha-acetoxy-hop-22(29)-ene. 3 alpha-hydroxylanosta-5,15-diene learn more is a new triterpenoid and is isolated for the first time from this genus.”
“We measured health utility scores of colorectal cancer (CRC) patients from a societal perspective in Japan.
Twenty-five Givinostat in vitro states of health were described: four metastatic states without severe adverse events (AEs), 16 metastatic states with Grade 3/4 AEs, four adjuvant states, and one terminal state. A total of 1,500 respondents stratified by age and gender were recruited randomly from the largest
Web-panel in Japan. Respondents were allocated randomly to three of the 25 health states and answered questionnaires by standard gamble (SG) and time trade-off (TTO) methods.
Although utility scores of metastatic CRC receiving XELOX (capecitabine plus oxaliplatin) chemotherapy were 0.48(SG and TTO) (with stoma) and 0.57(SG) or 0.59(TTO) (without stoma), utility scores of those receiving FOLFOX4 (5-fluorouracil/folinic acid and oxaliplatin) chemotherapy were 0.42(SG) or 0.43(TTO) (with stoma) and 0.52(SG) or 0.53(TTO) (without stoma). These differences between XELOX and FOLFOX4 were statistically significant (P = 0.0198 in SG and P = 0.0059 in TTO). Stage 3/4 AEs decreased utility scores to 0.35-0.4 and 0.4-0.45 in the presence and absence of stoma, respectively.